| |JULY 20238ICMR SOON TO START RESEARCH ON AMBULATORY CARE FOR NCDS IN PUBLIC HEALTH CARE SYSTEMS IN INDIAUS FDA APPROVES ZYNEX'S CM-1600 MONITOR FOR IMPROVED BLOOD & FLUID MANAGEMENTThe Indian Council of Medical Research (ICMR) has invited Expression of Interest (EOI) for Implementation Research Study on Ambulatory Care for Non-Communicable Diseases (NCDs) in Public Health Care Systems in India.The EoI is aimed at developing practical, scalable, and sustainable strategies that provide evidence-based effective management of non- communicable diseases in India's public healthcare systems under the National Programme for Non-Communicable Diseases (NP-NCD).There is a need to deliver effective NCD ambulatory care in public primary health care systems using a combination of strategies, including the use of available point-of-care testing for diagnosis and follow-up, capacity building of providers to reduce physician inertia, use of easy-to-use treatment algorithms, improved supply logistics of essential drugs and diagnostics and simplified data information systems.One such example is the India Hypertension Control Initiative (IHCI), built on the existing framework of NP-NCD since 2018, which is being implemented in 140+ districts of the country and has demonstrated reasonable success in registering and retaining patients with hypertension and controlling blood pressure.The IHCI was built on the World Health Organization (WHO)'s HEARTS strategies- simple drug and dose-specific protocols, uninterrupted availability of medications, patient-centered care, a team-based approach with task sharing, and a reliable information system. POZynex, Inc., an innovative medical technology company specialising in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has announced that the FDA has granted 510(k) market clearance for the company's CM-1600 blood and fluid volume monitoring device."I am pleased to announce FDA clearance for our second-generation blood and fluid volume monitor," said Zynex's founder and CEO, Thomas Sandgaard. "Our non-invasive, wireless technology aims to improve patient outcomes in hospital settings through better fluid management." The device works by monitoring multiple physiological changes in the patient's blood and fluid levels. We will continue to collect data in clinical trials in the future, and I am hopeful that the monitoring division will eventually contribute meaningful revenue to Zynex's already profitable pain management division."Three more products are in the works for Zynex's hospital monitoring division: a laser-based pulse oximeter, NiCO; a monitor for early detection of sepsis; and a non-invasive, laser-based monitor of total haemoglobin levels, HemeOx. The monitoring division is pre-revenue and plans to submit an application to the FDA in the fourth quarter of this year for its laser-based pulse oximeter.Zynex, which was founded in 1996, develops, manufactures, markets, and sells medical devices for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximeter monitoring systems for hospital use. POTOP STORIES
< Page 7 | Page 9 >